Early- and Late-Onset Pneumonia: Is This Still a Useful Classification?

Size: px
Start display at page:

Download "Early- and Late-Onset Pneumonia: Is This Still a Useful Classification?"

Transcription

1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2009, p Vol. 53, No /09/$ doi: /aac Copyright 2009, American Society for Microbiology. All Rights Reserved. Early- and Late-Onset Pneumonia: Is This Still a Useful Classification? Petra Gastmeier, 1,2 * Dorit Sohr, 2 Christine Geffers, 2 Henning Rüden, 2 Ralf-Peter Vonberg, 1 and Tobias Welte 3 Institute for Medical Microbiology and Hospital Epidemiology 1 and Department of Pneumology, 3 Medical School Hannover, Hannover, and Institute of Hygiene and Environmental Medicine, Charité University Medicine Berlin, Berlin, 2 Germany Received 8 August 2008/Returned for modification 8 October 2008/Accepted 7 April 2009 The choice of empirical treatment of nosocomial pneumonia in the intensive-care unit (ICU) used to rely on the interval after the start of mechanical ventilation. Nowadays, however, the question of whether in fact there is a difference in the distribution of causative pathogens is under debate. Data from 308 ICUs from the German National Nosocomial Infection Surveillance System, including information on relevant pathogens isolated in 11,285 cases of nosocomial pneumonia from 1997 to 2004, were used for our evaluation. Each individual pneumonia case was allocated either to early- or to late-onset pneumonia, with three differentiation criteria: onset on the 4th day, the 5th day, or the 7th day in the ICU. The frequency of pathogens was evaluated according to these categories. A total of 5,066 additional cases of pneumonia were reported from 2005 to 2006, after the CDC criteria had been modified. From 1997 to 2004, the most frequent microorganisms were Staphylococcus aureus (2,718 cases, including 720 with methicillin [meticillin]-resistant S. aureus), followed by Pseudomonas aeruginosa (1,837 cases), Klebsiella pneumoniae (1,305 cases), Escherichia coli (1,137 cases), Enterobacter spp. (937 cases), streptococci (671 cases), Haemophilus influenzae (509 cases), Acinetobacter spp. (493 cases), and Stenotrophomonas maltophilia (308 cases). The order of the four most frequent pathogens (accounting for 53.7% of all pathogens) was the same in both groups and was independent of the cutoff categories applied: S. aureus was first, followed by P. aeruginosa, K. pneumoniae, and E. coli. Thus, the predictabilities of the occurrence of pathogens were similar for the earlier (1997-to-2004) and later (2005-to- 2006) time frames. This classification is no longer helpful for empirical antibiotic therapy, since the pathogens are the same for both groups. For a long time it was common to distinguish between an early onset (the first 4 days) and a late onset (after the 4th day) of ventilator-associated pneumonia (VAP) (18). Early-onset nosocomial pneumonia was believed to be due primarily to gram-negative bacteria, such as Haemophilus influenzae, and methicillin (meticillin)-sensitive Staphylococcus aureus (MSSA) and Streptococcus pneumoniae. For late-onset nosocomial pneumonia, the most commonly encountered causative pathogens reported were higher-level antibiotic-resistant gram-negative bacteria, such as Pseudomonas aeruginosa, Acinetobacter spp., or methicillin-resistant S. aureus (MRSA). This classification leads to different strategies for empirical antimicrobial treatment: monotherapy with narrow-spectrum antibiotics for the treatment of early-onset pneumonia but broad-spectrum therapy for Pseudomonas spp. or MRSA with late-onset infection (2). Meanwhile, guidelines and articles that discuss this classification are using different criteria for distinguishing between early- and late-onset nosocomial pneumonia. Some authors regard the 4th day in the intensive-care unit (ICU) as the last day of an early onset (4, 6, 16, 20, 22), while others set the 5th (23) or even the 7th (11, 14, 24) day as the limit. Furthermore, it still remains uncertain from the relevant literature whether the given threshold refers to the number of days in the hospital * Corresponding author. Mailing address: Institute of Hygiene and Environmental Medicine, Charité University Medicine Berlin, Hindenburgdamm 27, D Berlin, Germany. Phone: Fax: petra.gastmeier@charite.de. Published ahead of print on 13 April or the number of days following intubation (23). The concept itself, though, still remains accepted in general (3, 23). During our surveillance activities in several ICUs, however, we got the impression that this widely used classification may no longer be appropriate for determining the antimicrobial therapy required. We have therefore used data from the German National Nosocomial Infection Surveillance System, KISS (Krankenhaus-Infektions-Surveillance-System), to investigate this question, drawing on a huge database provided by German ICUs (10). MATERIALS AND METHODS The ICU component of KISS was established in Since then, the number of participating ICUs has increased continuously (10). The method used by KISS is almost identical to the surveillance method of the National Nosocomial Infections Surveillance (NNIS) System in the United States (8). The definitions from the Centers for Disease Control and Prevention (CDC) (9) are used for the diagnosis of nosocomial infections in KISS as well. The KISS methodology for calculating device-associated infection rates, comparing infection rates, and recording complications also derives from the NNIS system. Whenever a nosocomial infection occurs, the pathogens identified in the specimen are reported to the surveillance system. As many as four pathogens can be recorded for each infection site. For S. aureus, it is also recorded whether the isolate is MSSA or MRSA. For the current analysis, we calculated the percentages of nosocomial pneumonia cases with MSSA, MRSA, P. aeruginosa, and other pathogens out of all the pneumonia cases identified on any given ICU day during the first 14 ICU days. In addition, we compared the pathogens identified according to three cutoffs (the 4th day, the 5th day, and the 7th day) to distinguish between earlyand late-onset nosocomial pneumonia. These days are numbered from the day of admission of the patient to the ICU. The first day on which clinical signs or symptoms of pneumonia were noticed or, alternatively, the day on which (positive) samples were drawn for microbiological testing (whichever happened 2714

2 VOL. 53, 2009 EARLY- AND LATE-ONSET PNEUMONIA 2715 TABLE 1. The nine pathogens most frequently identified in samples from patients with nosocomial pneumonia a No. (%) of isolates identified on the basis of: All materials sent for microbiological investigation (n 11,285) first) is considered the day of onset. To compare the two groups for the 7-day limit, relative risks with 95% confidence intervals were calculated. Since the CDC definitions of nosocomial pneumonia were recently modified (15), we also looked separately at the time frames 1997 to 2004 and 2005 to 2006 in order to evaluate whether this modification has influenced the distribution of pathogens in our surveillance system. Because the majority of pneumonia cases were diagnosed on the basis of clinical criteria and endotracheal aspirate cultures, we performed a distinct analysis for those pneumonia cases diagnosed by quantitative culture of bronchoalveolar lavage (BAL) specimens, because such samples are considered to yield more-accurate data than endotracheal aspirates (6). Uniform threshold values for cultured specimens in the diagnosis of pneumonia were 10 4 CFU per ml. RESULTS Quantitative cultures of BAL specimens only (n 1,609) S. aureus 2,718 (24.1) 450 (28.0) P. aeruginosa 1,837 (16.3) 318 (19.8) K. pneumoniae 1,305 (11.6) 159 (9.9) E. coli 1,137 (10.1) 187 (11.6) Enterobacter spp. 937 (8.3) 148 (9.2) S. pneumoniae 671 (6.0) 97 (6.0) Haemophilus spp. 509 (4.5) 72 (4.5) Acinetobacter spp. 493 (4.4) 77 (4.8) S. maltophilia 308 (2.7) 64 (4.0) The 1997-to-2004 time frame. Up to the end of 2004, we had an overview of 11,285 pneumonia cases from 308 ICUs monitored during 12,879 observation months (KISS). Most of the ICUs are interdisciplinary ICUs (48.1%), followed by surgical (21.4%), medical (19.2%), neurosurgical (3.6%), pediatric (3.2%), neurological (2.6%), and cardiosurgical (1.9%) ICUs. The proportion of pneumonia cases considered to be ventilator associated was 87.4%. The overall VAP rate was 7.5 cases per 1,000 ventilator days (German National Reference Centre for the Surveillance of Nosocomial Infections, 2006 [ In 1,305 cases of pneumonia (11.6%), no detectable pathogens were recorded. For the remaining 9,980 cases, a total of 14,911 pathogens were recorded, for an average of 1.5 pathogens per pneumonia case. In 1,609 cases (14.3% of all cases), the pathogens were identified by quantitative culture of BAL specimens. The nine most frequent pathogens, on the basis of all the material sent in for microbiological investigation or on the basis only of BAL fluid quantitative cultures, can be found in Table 1. The most frequent pathogen was S. aureus (2,718 cases, of which 720 were MRSA infections), followed by P. aeruginosa (1,837 cases), Klebsiella pneumoniae (1,305 cases), Escherichia coli (1,137 cases), Enterobacter spp. (937 cases), S. pneumoniae (671 cases), Haemophilus spp. (509 cases), Acinetobacter spp. (493 cases), and Stenotrophomonas maltophilia (308 cases). The order of frequency is almost identical for the two groups (based on all kinds of specimens or on BAL fluid cultures only). TABLE 2. Numbers of pneumonia cases according to the different limits for classification a Classification of pneumonia No. of cases (% of all cases) No. of VAP cases (% of all VAP cases) No. of cases identified by culture of BAL fluids (% of all BAL fluid cultureidentified cases) Early onset 1 4 days 2,235 (19.8) 1,799 (18.2) 315 (19.6) 1 5 days 3,271 (29.0) 2,705 (27.4) 463 (28.8) 1 7 days 5,124 (45.4) 4,325 (43.8) 747 (46.4) Late onset 4th day 9,050 (80.2) 8,080 (81.8) 1,294 (80.4) 5th day 8,041 (71.0) 7,174 (72.6) 1,146 (71.2) 7th day 6,161 (54.6) 5,554 (56.2) 862 (53.6) The distribution of pneumonia cases according to the categories of early- and late-onset pneumonia can be found in Table 2. This distribution is also almost identical for all VAP cases and for only those cases that were confirmed by culture of BAL specimens. Table 3 shows the number of isolates per 100 pneumonia cases for the same pathogens. The order of frequency of the four most frequent microorganisms is also shown in Table 3. There are no major differences in the order of frequency of pathogens, regardless of the definitions of early and late. The 7-day cutoff seems to be the most appropriate for evaluating differences between the two onset groups, because it yields groups with similar sizes and also corresponds to the median time of occurrence of pneumonia in our database (7 days). We therefore used this cutoff to calculate the relative risks of early- versus late-onset pneumonia caused by particular pathogens, by comparing the numbers of isolates per 100 pneumonia cases for the two groups (Table 4). After considering only those results with significant confidence intervals, we confirmed MSSA, S. pneumoniae, and Haemophilus spp. as early-onset pathogens and P. aeruginosa, MRSA, Enterobacter spp., Acinetobacter spp., and S. maltophilia as late-onset pathogens. The 2005-to-2006 time frame. When the CDC definitions of nosocomial pneumonia were changed, KISS adapted the diagnosis criteria accordingly. That is why, as mentioned in Materials and Methods, we evaluated pathogens from nosocomial pneumonia cases separately for this time period. An additional 5,068 cases of nosocomial pneumonia were reported during these 2 years. For 5,066 of those, data on the time between ICU admission and the onset of infection were also available. A total of 5,969 pathogens were reported for the 5,068 pneumonia cases (1.47 pathogens per case on average). The order of the five most frequent pathogens was shown to be the same regardless of the length of the patient s ICU stay before infection. There were no differences from the earlier time frame (1997 to 2004) in the order of frequency of pathogens.

3 2716 GASTMEIER ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 3. Isolates per 100 pneumonia cases for the most frequent microorganisms, together with the order of frequency of the four most frequent pathogens a No. of isolates per 100 pneumonia cases (order of frequency) Early-onset pneumonia Late-onset pneumonia 1 4 days 1 5 days 1 7 days 4th day 5th day 7th day S. aureus 25.7 (1st) 26.8 (1st) 26.9 (1st) 23.7 (1st) 23.0 (1st) 21.0 (1st) MSSA MRSA P. aeruginosa 11.6 (2nd) 11.6 (2nd) 11.9 (2nd) 17.4 (2nd) 16.1 (2nd) 19.9 (2nd) K. pneumoniae 10.8 (3rd) 10.7 (4th) 11.1 (3rd) 11.8 (3rd) 10.6 (3rd) 12.6 (3rd) E. coli 10.0 (4th) 10.8 (3rd) 10.6 (4th) 10.1 (4th) 8.7 (4th) 10.1 (4th) S. pneumoniae Enterobacter spp Haemophilus spp Acinetobacter spp S. maltophilia DISCUSSION TABLE 4. Relative risks of early- and late-onset pneumonia with particular pathogens a No. of isolates per 100 pneumonia cases Early onset (1 7 days) Late onset ( 7 days) Relative risk (95% CI) b Type of pathogen according to the time of onset c S. aureus ( ) Early MSSA ( ) Early MRSA ( ) Late P. aeruginosa ( ) Late K. pneumoniae ( ) E. coli ( ) S. pneumoniae ( ) Early Enterobacter spp ( ) Late Haemophilus spp ( ) Early Acinetobacter spp ( ) Late S. maltophilia ( ) Late a Calculated by comparing the numbers of isolates per 100 cases in early- and late-onset pneumonia, using the 7-day cutoff for distinguishing between the two groups. Data are from KISS, 1997 to b 95% CI, 95% confidence interval. c Recorded for significant results only. The administration of accurate and timely initial empirical antibiotic therapy has been shown to have a major impact on mortality from nosocomial pneumonia (1, 5, 7, 25). Because early-onset nosocomial pneumonia is most often reported as being due to antibiotic-sensitive pathogens, while late-onset nosocomial pneumonia is frequently caused by more-resistant pathogens, guidelines recommend monotherapy with narrowspectrum antibiotics for early-onset infections and broad-spectrum therapy for late-onset infections (2, 6, 12). To our knowledge, we present here the largest study of its kind ever published ( 300 ICUs contributing; surveillance of 16,000 cases of VAP; 20,000 pathogens recovered). According to our data, the order of frequency of microorganisms is almost the same in the two groups; the differences are not distinctive enough for a decision about appropriate initial therapy, regardless of the modification of the CDC definitions. The cutoff day used for distinguishing between early- and late-onset pneumonia also has only a minor impact. Thus, the absolute duration of mechanical ventilation seems to be insufficient for choosing the kind of antimicrobial treatment. That is why the classification of nosocomial pneumonia as early- or late-onset pneumonia should, in our view, no longer be recommended. In particular, the high percentage of P. aeruginosa pneumonia cases in the early-onset group, together with the increasing percentage of MRSA pneumonia, could lead to undertreatment of patients if one follows this principle of classification too rigidly. The frequent identification of P. aeruginosa and MRSA in the early-onset pneumonia group may be due to hospitalization prior to ICU admission and previous exposure to antibiotics. Micek et al. showed that an earlier hospital stay within 12 months increases the risk for infection by gram negative pathogens (19). Kothe et al. identified age and certain comorbidities as additional risk factors for colonization by gram-negative bacteria (17). The latest guidelines of the American Thoracic Society have already been modified and note that patients with early-onset pneumonia who have received antibiotics or have been hospitalized within the past 90 days have a greater risk of being colonized and infected with multiresistant pathogens and should be treated in the same way as patients with late-onset pneumonia (3). Other colleagues doubt the usefulness of this classification. Mosconi et al., comparing patients with early- and late-onset pneumonia, discovered similar risks of death in the two groups (21). This was also concluded by Heyland et al. for the 7-day limit (14) and by Ibrahim et al. for the 4-day limit (16). Giantsou et al. investigated this question, focusing on pneumonia cases diagnosed by BAL, and came to the same conclusion (11). Hedrick et al. did find some differences in the distribution of organisms in early-onset (predominantly gram-positive bacteria) and late-onset (predominantly gram-negative bacteria) VAP among trauma surgical patients, but they were unable to detect any significant differences among nontrauma surgical patients, and no differences in mortality between early- and late onset pneumonia were found either in trauma patients or in nontrauma patients (13). Verhamme et al. reported that

4 VOL. 53, 2009 EARLY- AND LATE-ONSET PNEUMONIA 2717 pathogens potentially resistant to multiple drugs were isolated in more than half (52%) of cases of early-onset ICU-acquired pneumonia (26). However, all these authors used data from individual institutions, and their data may not be representative of all intensive-care patients. Our analysis, too, has some potential limitations: We used the sensitive, but somewhat less specific, CDC criteria for diagnosing nosocomial infections (9), which can lead to classifying patients as pneumonia patients when there is actually no pneumonia. These criteria are based mainly on clinical signs and symptoms as well as on microbiological findings. Since 2005, radiological abnormalities and/or changes have always been required in order to diagnose any case of pneumonia. However, there is not always a proven link between the results from the microbiological laboratory and the infection. For example, S. maltophilia is detected quite frequently in specimens from the respiratory tract but has rather low pathogenicity and thus may not be the actual cause of infection. In interpreting the data, the diagnostic quality of the individual ICUs should also be taken into account. Depending on the type of ICU, the frequency of disease and the level of diagnostic effort may differ. Only a subgroup of ICUs routinely perform BAL when nosocomial pneumonia is suspected, while others use clinical criteria for diagnosing pneumonia in combination with the identification of pathogens from tracheal secretions. Only in 14.3% of the pneumonia cases in our database were the pathogens identified from bronchoalveolar secretions or blood. Some uncertainty remains, therefore, as to whether some patients included in our study did not in fact have infections but were only colonized by the pathogens. However, most probably this is true for early- as well as late-onset pneumonia. In addition, the order of frequency did not change substantially when only the cases diagnosed by quantitative culture of BAL specimens were considered. Furthermore, as mentioned earlier, as many as four pathogens can be recorded and referred to the surveillance system for each pneumonia case. Thus, it is almost impossible to identify a single causative organism for a specific nosocomial infection. Instead, all microorganisms were considered equally for this analysis. Moreover, usually many different microbiology laboratories are involved in national surveillance systems. Almost all the laboratories in our surveillance system apply standard procedures, although the diagnostic quality may still differ. However, differences in laboratory practice most probably influenced both categories in the same way. Despite the limitations mentioned above, we conclude that our data do confirm the classification of the most important pathogens that cause pneumonia. However, in our findings, the distribution of pathogens remains unchanged regardless of the time of onset of symptoms. Thus, in our view, the concept of early- and late-onset pneumonia pathogens is no longer helpful for the management of empirical antibiotic therapy. Empirical antimicrobial therapy should be identical for both groups. Since inadequate initial antimicrobial treatment increases the risk of a fatal outcome of VAP, we recommend starting therapy with broad-spectrum antibiotics at high dosages. However, as soon as a microbiological result is available that narrows the spectrum of potential causative agents (which usually happens after approximately 3 days), the antimicrobial regimen should be modified accordingly. Other diagnostic tools, such as rapid Gram staining, urinary Legionella antigen testing, or a multiplex PCR test for viral respiratory agents, could also contribute to more-rapid diagnosis of the causative agent and thus restrict the use of antibiotics. In addition, more randomized, controlled trials are necessary to address the issue of risk factors for the development of VAP and the impact of multidrug-resistant pathogens on morbidity and mortality due to this disease. REFERENCES 1. Alvarez-Lerma, F., et al Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med. 22: American Thoracic Society Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, November Am. J. Respir. Crit. Care Med. 153: American Thoracic Society Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171: Baker, A. M., J. W. Meredith, and E. F. Haponik Pneumonia in intubated trauma patients. Microbiology and outcomes. Am. J. Respir. Crit. Care Med. 153: Celis, R., A. Torres, J. M. Gatell, M. Almela, R. Rodríguez-Roisin, and A. Agustí-Vidal Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest 93: Chastre, J., and J. Y. Fagon Ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 165: Dupont, H., H. Mentec, J. P. Sollet, and G. Bleichner Impact of appropriateness of initial antibiotic therapy on the outcome of ventilatorassociated pneumonia. Intensive Care Med. 27: Emori, T. G., D. H. Culver, T. C. Horan, W. R. Jarvis, J. W. White, D. R. Olson, S. Banerjee, J. R. Edwards, W. J. Martone, and R. P. Gaynes National Nosocomial Infections Surveillance System (NNIS): description of surveillance methods. Am. J. Infect. Control 19: Garner, J. S., W. R. Jarvis, T. G. Emori, T. C. Horan, and J. M. Hughes CDC definitions for nosocomial infections, Am. J. Infect. Control 16: Gastmeier, P., C. Geffers, D. Sohr, M. Dettenkofer, F. Daschner, and H. Ruden Five years working with the German nosocomial infection surveillance system (Krankenhaus Infektions Surveillance System). Am. J. Infect. Control 31: Giantsou, E., N. Liratzopoulos, E. Efraimidou, M. Panopoulou, E. Alepopoulou, S. Kartali-Ktenidou, G. I. Minopoulos, S. Zakynthinos, and K. I. Manolas Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria. Intensive Care Med. 31: Giard, M., A. Lepape, B. Allaouchiche, C. Guerin, J. J. Lehot, M. O. Robert, G. Fournier, D. Jacques, D. Chassard, P. Y. Gueugniaud, F. Artru, P. Petit, D. Robert, I. Mohammedi, R. Girard, J. C. Cetre, M. C. Nicolle, J. Grando, J. Fabry, and P. Vanhems Early- and late-onset ventilator-associated pneumonia acquired in the intensive care unit: comparison of risk factors. J. Crit. Care 23: Hedrick, T. L., R. L. Smith, S. T. McElearney, H. L. Evans, P. W. Smith, T. L. Pruett, J. S. Young, and R. G. Sawyer Differences in early- and late-onset ventilator-associated pneumonia between surgical and trauma patients in a combined surgical or trauma intensive care unit. J. Trauma 64: Heyland, D. K., D. J. Cook, L. Griffith, S. P. Keenan, and C. Brun-Buisson for the Canadian Critical Care Trials Group The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. Am. J. Respir. Crit. Care Med. 159: Horan, T. C., and R. P. Gaynes Surveillance of nosocomial infections, p In C. G. Mayhall (ed.), Hospital epidemiology and infection control. Lippincott Williams & Wilkins, Philadelphia, PA. 16. Ibrahim, E. H., S. Ward, G. Sherman, and M. H. Kollef A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest 117: Kothe, H., T. Bauer, R. Marre, N. Suttorp, T. Welte, and K. Dalhoff Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur. Respir. J. 32: Langer, M., M. Cigada, M. Mandelli, P. Mosconi, and G. Tognoni Early onset pneumonia: a multicenter study in intensive care units. Intensive Care Med. 13: Micek, S. T., K. E. Kollef, R. M. Reichley, N. Roubinian, and M. H. Kollef Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob. Agents Chemother. 51:

5 2718 GASTMEIER ET AL. ANTIMICROB. AGENTS CHEMOTHER. 20. Moine, P., J. F. Timsit, A. De Lassence, G. Troche, J. P. Fosse, C. Alberti, and Y. Cohen Mortality associated with late-onset pneumonia in the intensive care unit: results of a multi-center cohort study. Intensive Care Med. 28: Mosconi, P., M. Langer, M. Cigada, M. Mandelli, et al Epidemiology and risk factors of pneumonia in critically ill patients. Eur. J. Epidemiol. 7: Prod hom, G., P. Leuenberger, J. Koerfer, A. Blum, R. Chiolero, M. D. Schaller, C. Perret, O. Spinnler, J. Blondel, H. Siegrist, L. Saghafi, D. Blanc, and P. Francioli Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer. A randomized controlled trial. Ann. Intern. Med. 120: Torres, A., and J. Carlet for the European Task Force on Ventilator-Associated Pneumonia Ventilator-associated pneumonia. Eur. Respir. J. 17: Trouillet, J. L., J. Chastre, A. Vuagnat, M. L. Joly-Guillou, D. Combaux, M. C. Dombret, and C. Gibert Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am. J. Respir. Crit. Care Med. 157: Vallés, J., A. Pobo, O. Garcia-Esquirol, D. Mariscal, J. Real, and R. Fernandez Excess ICU mortality attributable to ventilator-associated pneumonia: the role of early vs late onset. Intensive Care Med. 33: Verhamme, K. M., W. De Coster, L. De Roo, H. De Beenhouwer, G. Nollet, J. Verbeke, I. Demeyer, and P. Jordens s in early-onset and late-onset intensive care unit-acquired pneumonia. Infect. Control Hosp. Epidemiol. 28:

Institute of Hygiene and Environmental Medicine. Charité University Medicine Berlin. Mail:

Institute of Hygiene and Environmental Medicine. Charité University Medicine Berlin. Mail: AAC Accepts, published online ahead of print on 13 April 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.01070-08 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.

More information

HEALTHCARE-ASSOCIATED PNEUMONIA: EPIDEMIOLOGY, MICROBIOLOGY & PATHOPHYSIOLOGY

HEALTHCARE-ASSOCIATED PNEUMONIA: EPIDEMIOLOGY, MICROBIOLOGY & PATHOPHYSIOLOGY HEALTHCARE-ASSOCIATED PNEUMONIA: EPIDEMIOLOGY, MICROBIOLOGY & PATHOPHYSIOLOGY David Jay Weber, M.D., M.P.H. Professor of Medicine, Pediatrics, & Epidemiology Associate Chief Medical Officer, UNC Health

More information

Guess or get it right?

Guess or get it right? Guess or get it right? Antimicrobial prescribing in the 21 st century Robert Masterton Traditional Treatment Paradigm Conservative start with workhorse antibiotics Reserve more potent drugs for non-responders

More information

Healthcare-associated infections acquired in intensive care units

Healthcare-associated infections acquired in intensive care units SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Healthcare-associated infections acquired in intensive care units Key facts In 2015, 11 788 (8.3%) of patients staying in an intensive care unit

More information

Diagnosis of Ventilator- Associated Pneumonia: Where are we now?

Diagnosis of Ventilator- Associated Pneumonia: Where are we now? Diagnosis of Ventilator- Associated Pneumonia: Where are we now? Gary French Guy s & St. Thomas Hospital & King s College, London BSAC Guideline 2008 Masterton R, Galloway A, French G, Street M, Armstrong

More information

Abstract. Introduction

Abstract. Introduction ORIGINAL ARTICLE INFECTIOUS DISEASES Accuracy of American Thoracic Society/Infectious Diseases Society of America criteria in predicting infection or colonization with multidrug-resistant bacteria at intensive-care

More information

PREVALENCE PATTERN OF MORBIDITY AND MORTALITY IN VENTILATION ASSOCIATED PNEUMONIA (VAP) PATIENTS OF INTENSIVE CARE UNIT (ICU) IN MAHARASHTRA REGION.

PREVALENCE PATTERN OF MORBIDITY AND MORTALITY IN VENTILATION ASSOCIATED PNEUMONIA (VAP) PATIENTS OF INTENSIVE CARE UNIT (ICU) IN MAHARASHTRA REGION. Original research article International Journal of Medical Science and Education pissn- 2348 4438 eissn-2349-3208 PREVALENCE PATTERN OF MORBIDITY AND MORTALITY IN VENTILATION ASSOCIATED PNEUMONIA (VAP)

More information

Nosocomial infections surveillance in RIPAS Hospital

Nosocomial infections surveillance in RIPAS Hospital Original Article Brunei Int Med J. 212; 8 (6): 32-333 Nosocomial infections surveillance in RIPAS Hospital Muppidi SATYAVANI, 1, 2 Junita MOMIN, ² and Samuel Kai San YAPP 2, 3 ¹ Department of Microbiology,

More information

Bacteriological profile and outcome of Ventilator associated pneumonia in Intensive care unit of a tertiary care centre

Bacteriological profile and outcome of Ventilator associated pneumonia in Intensive care unit of a tertiary care centre ORIGINAL ARTICLE ASIAN JOURNAL OF MEDICAL SCIENCES Bacteriological profile and outcome of Ventilator associated pneumonia in Intensive care unit of a tertiary care centre Ravi K 1, Maithili TM 2, David

More information

The Attributable Morbidity and Mortality of Ventilator-Associated Pneumonia in the Critically Ill Patient

The Attributable Morbidity and Mortality of Ventilator-Associated Pneumonia in the Critically Ill Patient The Attributable Morbidity and Mortality of Ventilator-Associated Pneumonia in the Critically Ill Patient DAREN K. HEYLAND, DEBORAH J. COOK, LAUREN GRIFFITH, SEAN P. KEENAN, and CHRISTIAN BRUN-BUISSON

More information

CHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement

CHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement CHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement Evidence-Based Assessment of Diagnostic Tests for Ventilator- Associated Pneumonia* Executive Summary Ronald F. Grossman, MD, FCCP; and Alan Fein, MD,

More information

ANWICU knowledge

ANWICU knowledge ANWICU knowledge www.anwicu.org.uk This presenta=on is provided by ANWICU We are a collabora=ve associa=on of ICUs in the North West of England. Permission to provide this presenta=on has been granted

More information

HEALTHCARE-ASSOCIATED PNEUMONIA: DIAGNOSIS, TREATMENT & PREVENTION

HEALTHCARE-ASSOCIATED PNEUMONIA: DIAGNOSIS, TREATMENT & PREVENTION HEALTHCARE-ASSOCIATED PNEUMONIA: DIAGNOSIS, TREATMENT & PREVENTION David Jay Weber, M.D., M.P.H. Professor of Medicine, Pediatrics, & Epidemiology Associate Chief Medical Officer, UNC Health Care Medical

More information

Usefulness of Gram staining of tracheal aspirates in initial therapy for ventilator-associated pneumonia in extremely preterm neonates

Usefulness of Gram staining of tracheal aspirates in initial therapy for ventilator-associated pneumonia in extremely preterm neonates (2010) 30, 270 274 r 2010 Nature Publishing Group All rights reserved. 0743-8346/10 $32 www.nature.com/jp ORIGINAL ARTICLE Usefulness of Gram staining of tracheal aspirates in initial therapy for ventilator-associated

More information

Ventilator Associated

Ventilator Associated Ventilator Associated Pneumonia: Key and Controversial Issues Christopher P. Michetti, MD, FACS Inova Fairfax Hospital, Falls Church, VA Forrest Dell Moore, MD, FACS Banner Healthcare System, Phoenix,

More information

Robert A. Weinstein, MD Stroger (Cook County) Hospital Rush Medical College April 6, Disclosure: Grant funding from CDC & Sage Products, Inc.

Robert A. Weinstein, MD Stroger (Cook County) Hospital Rush Medical College April 6, Disclosure: Grant funding from CDC & Sage Products, Inc. Robert A. Weinstein, MD Stroger (Cook County) Hospital Rush Medical College April 6, 2010 Disclosure: Grant funding from CDC & Sage Products, Inc. How the BLEEP should I know? Only problem how we gonna

More information

EUROANESTHESIA 2007 Munich, Germany, 9-12 June RC4

EUROANESTHESIA 2007 Munich, Germany, 9-12 June RC4 POSTOPERATIVE PNEUMONIA EUROANESTHESIA 2007 Munich, Germany, 9-12 June 2007 12RC4 HERVÉ DUPONT Anaesthesiology and Intensive Care Medicine North University Hospital Amiens, France Saturday Jun 9, 2007

More information

Aminoglycosides as an antibiotic class maintain

Aminoglycosides as an antibiotic class maintain SURGICAL INFECTIONS Volume 17, Number 3, 2016 ª Mary Ann Liebert, Inc. DOI: 10.1089/sur.2015.276 An Argument for the Use of Aminoglycosides in the Empiric Treatment of Ventilator-Associated Pneumonia Addison

More information

VAP Prevention bundles

VAP Prevention bundles VAP Prevention bundles Dr. Shafiq A.Alimad MD Head of medical department at USTH YICID workshop, 15-12-2014 Care Bundles What are they & why use them? What are Care Bundles? Types of Care Bundles available

More information

Surveillance of Surgical Site Infection in Surgical Hospital Wards in Bulgaria,

Surveillance of Surgical Site Infection in Surgical Hospital Wards in Bulgaria, International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 01 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.701.361

More information

Soshi Hashimoto 1 and Nobuaki Shime 1,2*

Soshi Hashimoto 1 and Nobuaki Shime 1,2* Hashimoto and Shime Journal of Intensive Care 2013, 1:2 RESEARCH Open Access Evaluation of semi-quantitative scoring of Gram staining or semi-quantitative culture for the diagnosis of ventilator-associated

More information

Early gastrostomy reduces the rate of ventilator-associated pneumonia in stroke or head injury patients

Early gastrostomy reduces the rate of ventilator-associated pneumonia in stroke or head injury patients Eur Respir J 2005; 26: 106 111 DOI: 10.1183/09031936.05.00096104 CopyrightßERS Journals Ltd 2005 Early gastrostomy reduces the rate of ventilator-associated pneumonia in stroke or head injury patients

More information

Clinical characteristics of health care-associated pneumonia in a Korean teaching hospital

Clinical characteristics of health care-associated pneumonia in a Korean teaching hospital Respiratory Medicine (2010) 104, 1729e1735 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Clinical characteristics of health care-associated pneumonia in a Korean teaching

More information

Community Acquired & Nosocomial Pneumonias

Community Acquired & Nosocomial Pneumonias Community Acquired & Nosocomial Pneumonias IDSA/ATS 2007 & 2016 Guidelines José Luis González, MD Clinical Assistant Professor of Medicine Outline Intro - Definitions & Diagnosing CAP treatment VAP & HAP

More information

GUIDE TO INFECTION CONTROL IN THE HOSPITAL. Carbapenem-resistant Enterobacteriaceae

GUIDE TO INFECTION CONTROL IN THE HOSPITAL. Carbapenem-resistant Enterobacteriaceae GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 47: Carbapenem-resistant Enterobacteriaceae Authors E-B Kruse, MD H. Wisplinghoff, MD Chapter Editor Michelle Doll, MD, MPH) Topic Outline Key Issue Known

More information

Pradeep Morar, MD; Zvoru Makura, MD; Andrew Jones, MD; Paul Baines, MD; Andrew Selby, MD; Julie Hughes, RGN; and Rick van Saene, MD

Pradeep Morar, MD; Zvoru Makura, MD; Andrew Jones, MD; Paul Baines, MD; Andrew Selby, MD; Julie Hughes, RGN; and Rick van Saene, MD Topical Antibiotics on Tracheostoma Prevents Exogenous Colonization and Infection of Lower Airways in Children* Pradeep Morar, MD; Zvoru Makura, MD; Andrew Jones, MD; Paul Baines, MD; Andrew Selby, MD;

More information

BACTERIOLOGY OF POSTOPERATIVE PNEUMONIA EOLE STUDY Dupont H ICM 2003, 29,

BACTERIOLOGY OF POSTOPERATIVE PNEUMONIA EOLE STUDY Dupont H ICM 2003, 29, Pneumonies: classification Pneumonies communautaires Pneumonies associées aux soins Non nosocomiales Nosocomiales Malade ventilé précoces tardives Malade non ventilé The concept of Health Care Associated

More information

Pneumonia (PNEU) and Ventilator-Associated Pneumonia (VAP) Prevention. Basics of Infection Prevention 2-Day Mini-Course 2016

Pneumonia (PNEU) and Ventilator-Associated Pneumonia (VAP) Prevention. Basics of Infection Prevention 2-Day Mini-Course 2016 Pneumonia (PNEU) and Ventilator-Associated Pneumonia (VAP) Prevention Basics of Infection Prevention 2-Day Mini-Course 2016 Objectives Differentiate long term care categories of respiratory infections

More information

Outbreaks in neonatal intensive care units They are not like others

Outbreaks in neonatal intensive care units They are not like others neonatal intensive care units They are not like others etra Gastmeier, MD, a Andrea Loui, MD, b Sabine Stamm-Balderjahn, MD, c Sonja Hansen, MD, c Irina Zuschneid, MD, c Dorit Sohr, hd, c Michael Behnke,

More information

All previously published papers and figures were reproduced with permission from the publisher.

All previously published papers and figures were reproduced with permission from the publisher. All previously published papers and figures were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by Larserics Digital Print AB. Petra Hyllienmark, 2013 ISBN ISBN

More information

BIP Endotracheal Tube

BIP Endotracheal Tube Bactiguard Infection Protection BIP Endotracheal Tube For prevention of healthcare associated infections Ventilator associated pneumonia Infections of the respiratory tract are serious and common healthcare

More information

Preventing & Controlling the Spread of Infection

Preventing & Controlling the Spread of Infection Preventing & Controlling the Spread of Infection Contributors: Alice Pong M.D., Hospital Epidemiologist Chris Abe, R.N., Senior Director Ancillary and Support Services Objectives Review the magnitude of

More information

THE MICROBIOLOGICAL PROFILE OF VENTILATOR ASSOCIATED PNEUMONIA.

THE MICROBIOLOGICAL PROFILE OF VENTILATOR ASSOCIATED PNEUMONIA. THE MICROBIOLOGICAL PROFILE OF VENTILATOR ASSOCIATED PNEUMONIA. Dr. Poonam C. Sharma, Dr. S. S. Raut, Dr. S. R. More, Dr. V. S. Rathod, Dr. V. M. Gujar. 1. Post Graduate Student, Department of Microbiology,

More information

Work up of Respiratory & Wound Cultures:

Work up of Respiratory & Wound Cultures: Work up of Respiratory & Wound Cultures: Culture work up 2 Systematic approaches 1 Work up of Respiratory & Wound Cultures Resident flora Colonizing organisms Pathogens 2 Work up of Respiratory & Wound

More information

Nosocomial Pneumonia. <5 Days: Non-Multidrug-Resistant Bacteria

Nosocomial Pneumonia. <5 Days: Non-Multidrug-Resistant Bacteria Nosocomial Pneumonia Meredith Deutscher, MD Troy Schaffernocker, MD Ohio State University Burden of Hospital-Acquired Pneumonia Second most common nosocomial infection in the U.S. 5-10 episodes per 1000

More information

Work-up of Respiratory Specimens Now you can breathe easier

Work-up of Respiratory Specimens Now you can breathe easier 34 th Annual Meeting Southwestern Association of Clinical Microbiology Work-up of Respiratory Specimens Now you can breathe easier Yvette S. McCarter, PhD, D(ABMM) Director, Clinical Microbiology Laboratory

More information

Marcos I. Restrepo, MD, MSc, FCCP

Marcos I. Restrepo, MD, MSc, FCCP Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.

More information

Utility of Gram stain in the clinical management of suspected ventilator-associated pneumonia Secondary analysis of a multicenter randomized trial

Utility of Gram stain in the clinical management of suspected ventilator-associated pneumonia Secondary analysis of a multicenter randomized trial Journal of Critical Care (2008) 23, 74 81 Utility of Gram stain in the clinical management of suspected ventilator-associated pneumonia Secondary analysis of a multicenter randomized trial M. Albert MD

More information

Sequential microbiological monitoring of tracheal aspirates in intubated patients admitted to a pediatric intensive care unit

Sequential microbiological monitoring of tracheal aspirates in intubated patients admitted to a pediatric intensive care unit 0021-7557/05/81-01/29 Jornal de Pediatria Copyright 2005 by Sociedade Brasileira de Pediatria ORIGINAL ARTICLE Sequential microbiological monitoring of tracheal aspirates in intubated patients admitted

More information

HAP/VAP care bundle interventions - a UK approach. Dr R G Masterton NHS Ayrshire & Arran

HAP/VAP care bundle interventions - a UK approach. Dr R G Masterton NHS Ayrshire & Arran HAP/VAP care bundle interventions - a UK approach Dr R G Masterton NHS Ayrshire & Arran How Hazardous Is Health Care? (Leape and Amalberti) Total lives lost per year 100,000 10,000 1,000 100 10 1 HAZARDOUS

More information

Influenza A (H1N1)pdm09 in Minnesota Epidemiology

Influenza A (H1N1)pdm09 in Minnesota Epidemiology Influenza A (H1N1)pdm09 in Minnesota Epidemiology Infectious Disease Epidemiology, Prevention and Control Division PO Box 64975 St. Paul, MN 55164-0975 Number of Influenza Hospitalizations by Influenza

More information

Clinical Practice Guidelines for Nursing- and Healthcareassociated Pneumonia (NHCAP) [Complete translation] $

Clinical Practice Guidelines for Nursing- and Healthcareassociated Pneumonia (NHCAP) [Complete translation] $ respiratory investigation 51 (2013) 103 126 Contents lists available at SciVerse ScienceDirect Respiratory Investigation journal homepage: www.elsevier.com/locate/resinv Guideline Clinical Practice Guidelines

More information

Influenza-Associated Pediatric Deaths Case Report Form

Influenza-Associated Pediatric Deaths Case Report Form STATE USE ONLY DO NOT SEND INFORMATION IN THIS SECTION TO CDC Form approved OMB No. 0920-0007 Last Name: First Name: County: Address: City: State, Zip: Patient Demographics 1. State: 2. County: 3. State

More information

Effects of isolation rooms on the prevalence of hospital acquired pneumonia in a respiratory ICU #

Effects of isolation rooms on the prevalence of hospital acquired pneumonia in a respiratory ICU # European Review for Medical and Pharmacological Sciences Effects of isolation rooms on the prevalence of hospital acquired pneumonia in a respiratory ICU # 2013; 17(Suppl 1): 2-8 I. UCGUN, C.E. DAGLI*,

More information

Hospital-acquired pneumonia

Hospital-acquired pneumonia Key points Hospital-acquired pneumonia has a maj impact in terms of mtality and mbidity. Empirical treatment approach is still the best course of action. Prevention is of critical imptance. REVIEW Hospital-acquired

More information

Influenza-Associated Pediatric Mortality Case Report Form Form Approved OMB No

Influenza-Associated Pediatric Mortality Case Report Form Form Approved OMB No Influenza-Associated Pediatric Mortality Case Report Form Form Approved OMB No. 0920-0004 STATE USE ONLY DO NOT SEND INFORMATION IN THIS SECTION TO CDC Last Name: First Name: County: Address: City: State,

More information

Description of Respiratory Microbiology of Children With Long-Term Tracheostomies

Description of Respiratory Microbiology of Children With Long-Term Tracheostomies Description of Respiratory Microbiology of Children With Long-Term Tracheostomies Rachael McCaleb PharmD, Robert H Warren MD, Denise Willis RRT-NPS, Holly D Maples PharmD, Shasha Bai PhD, and Catherine

More information

Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units

Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Annual report of data from January 2010 to December 2010 Scottish Intensive Care Society Audit Group 1 Health Protection

More information

Enhanced EARS-Net Surveillance 2017 First Half

Enhanced EARS-Net Surveillance 2017 First Half 1 Enhanced EARS-Net Surveillance 2017 First Half In this report Main results for 2017, first half Breakdown of factors by organism and resistance subtype Device-association Data quality assessment Key

More information

Original Article Mahidol Univ J Pharm Sci 2015; 42 (4), MT. Nguyen 1, TD. Dang Nguyen 1* 1

Original Article Mahidol Univ J Pharm Sci 2015; 42 (4), MT. Nguyen 1, TD. Dang Nguyen 1* 1 Original Article Mahidol Univ J Pharm Sci 2015; 42 (4), 195-202 Investigation on hospital-acquired pneumonia and the association between hospital-acquired pneumonia and chronic comorbidity at the Department

More information

Correlation of Postoperative Wound Infection with Intraoperative Culture Results and Duration of Operation

Correlation of Postoperative Wound Infection with Intraoperative Culture Results and Duration of Operation POSTOPERATIVE THE IRAQI POSTGRADUATE WOUND INFECTION MEDICAL JOURNAL Correlation of Postoperative Wound Infection with Intraoperative Culture Results and Duration of Operation INTRODUCTION: Infection is

More information

Enhanced EARS-Net Surveillance REPORT FOR 2012 DATA

Enhanced EARS-Net Surveillance REPORT FOR 2012 DATA Enhanced EARS-Net Surveillance REPORT FOR DATA 1 In this report Main results for Proposed changes to the enhanced programme Abbreviations Used Here BSI Bloodstream Infections CVC Central Venous Catheter

More information

Multivariate Analysis of the Factors Associated With the Risk of Pneumonia in Intensive Care Units

Multivariate Analysis of the Factors Associated With the Risk of Pneumonia in Intensive Care Units BJID 2007; 11 (June) 339 Multivariate Analysis of the Factors Associated With the Risk of Pneumonia in Intensive Care Units Cláudia Maria Dantas de Maio Carrilho 1, Cintia Magalhães Carvalho Grion 1, Ana

More information

Intensive Care Unit Associated Infection National Surveillance Programme

Intensive Care Unit Associated Infection National Surveillance Programme Intensive Care Unit Associated Infection National Surveillance Programme Pilot Report 2011 1 Health Protection Scotland is a division of NHS National Services Scotland. Health Protection Scotland website:

More information

Hospital-acquired Pneumonia

Hospital-acquired Pneumonia Hospital-acquired Pneumonia Hospital-acquired pneumonia (HAP) Pneumonia that occurs at least 2 days after hospital admission. The second most common and the leading cause of death due to hospital-acquired

More information

Epidemiology of Infectious Complications of H1N1 Influenza Virus Infection

Epidemiology of Infectious Complications of H1N1 Influenza Virus Infection Epidemiology of Infectious Complications of H1N1 Influenza Virus Infection Lyn Finelli, DrPH, MS Lead, Influenza Surveillance and Outbreak Response Epidemiology and Prevention Branch Influenza Division

More information

Jean-Yves Fagon,* Jean Chastre, Yves Domart, Jean-Louis Trnuillet, and Claude Gibert

Jean-Yves Fagon,* Jean Chastre, Yves Domart, Jean-Louis Trnuillet, and Claude Gibert 538 Mortality Due to Ventilator-Associated Pneumonia or Colonization with Pseudomonas or Acinetobacter Species: Assessment by Quantitative Culture of Samples Obtained by a Protected Specimen Brush Jean-Yves

More information

The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia

The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia JORDI RELLO, MIGUEL GALLEGO, DOLORS MARISCAL, ROSARIO SOÑORA, and JORDI VALLES Intensive Care, Respiratory and Microbiology

More information

Hospital Acquired Pneumonias

Hospital Acquired Pneumonias Hospital Acquired Pneumonias Hospital Acquired Pneumonia ( HAP ) Hospital acquired pneumonia ( HAP ) is defined as an infection of the lung parenchyma developing during hospitalization and not present

More information

Does Using a Laparoscopic Approach to Cholecystectomy Decrease the Risk of Surgical Site Infection?

Does Using a Laparoscopic Approach to Cholecystectomy Decrease the Risk of Surgical Site Infection? ANNALS OF SURGERY Vol. 237, No. 3, 358 362 2003 Lippincott Williams & Wilkins, Inc. Does Using a Laparoscopic Approach to Cholecystectomy Decrease the Risk of Surgical Site Infection? Chesley Richards,

More information

Epidemiology and Microbiology of Hospital-Acquired Pneumonia

Epidemiology and Microbiology of Hospital-Acquired Pneumonia Epidemiology and Microbiology of Hospital-Acquired Pneumonia Paresh J. Patel, M.D., 1 Kenneth V. Leeper Jr., M.D., 1 and John E. McGowan Jr., M.D. 2 ABSTRACT Hospital-acquired pneumonia (HAP) is the second

More information

Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 April - 30 June 2014

Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 April - 30 June 2014 Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 April - 3 June 214 1. The cumulative cases report since December 21 and cases report during April to June 214 During 1 April to 3 June

More information

Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units

Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Annual report of data from January 2011 to December 2011 Scottish Intensive Care Society Audit Group Health Protection

More information

Aerosolized Antibiotics in Mechanically Ventilated Patients

Aerosolized Antibiotics in Mechanically Ventilated Patients Aerosolized Antibiotics in Mechanically Ventilated Patients Gerald C Smaldone MD PhD Introduction Topical Delivery of Antibiotics to the Lung Tracheobronchitis Aerosolized Antibiotic Delivery in the Medical

More information

The Clinical Management of Hospital Acquired Pneumonia. NHS Ayrshire & Arran

The Clinical Management of Hospital Acquired Pneumonia. NHS Ayrshire & Arran The Clinical Management of Hospital Acquired Pneumonia Dr R G Masterton NHS Ayrshire & Arran What s new in HAP/VAP? Care bundles MRSA VAP Improving outcomes with current antimicrobial New antimicrobials

More information

Clinical Practice Management Guideline for Ventilator-Associated Pneumonia: Diagnosis, Treatment & Prevention

Clinical Practice Management Guideline for Ventilator-Associated Pneumonia: Diagnosis, Treatment & Prevention Clinical for Ventilator-Associated Pneumonia: Diagnosis, Treatment & Prevention Background Ventilator-associated pneumonia (VAP), a pneumonia that develops 48hrs after initiation of mechanical ventilation,

More information

From the labo to the ICU: Surveillance cultures in daily ICU practice. Pieter Depuydt MD PhD Dept. Intensive Care Ghent University Hospital

From the labo to the ICU: Surveillance cultures in daily ICU practice. Pieter Depuydt MD PhD Dept. Intensive Care Ghent University Hospital From the labo to the ICU: Surveillance cultures in daily ICU practice Pieter Depuydt MD PhD Dept. Intensive Care Ghent University Hospital Question 1: What is the current practice of surveillance cultures

More information

Methicillin-Resistant Staphylococcus aureus (MRSA) S urveillance Report 2008 Background Methods

Methicillin-Resistant Staphylococcus aureus (MRSA) S urveillance Report 2008 Background Methods Methicillin-Resistant Staphylococcus aureus (MRSA) Surveillance Report 2008 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services

More information

Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units

Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Annual report of data from January - December 2012 Scottish Intensive Care Society Audit Group Health Protection Scotland

More information

Nosocomial Infection in a Pediatric Intensive Care Unit in a Developing Country

Nosocomial Infection in a Pediatric Intensive Care Unit in a Developing Country BJID 2003; 7 (December) 375 Nosocomial Infection in a Pediatric Intensive Care Unit in a Developing Country Marcelo L. Abramczyk 1,2, Werther B. Carvalho 1,2, Eduardo S. Carvalho 2 and Eduardo A. S. Medeiros

More information

KIMBERLY-CLARK* MICROCUFF* Endotracheal Tube.. Revolutionary cuff material designed to reduce micro-aspiration

KIMBERLY-CLARK* MICROCUFF* Endotracheal Tube.. Revolutionary cuff material designed to reduce micro-aspiration KIMBERLY-CLARK* MICROCUFF* Endotracheal Tube.. Revolutionary cuff material designed to reduce micro-aspiration Ventilator-Associated Pneumonia VAP is a major clinical concern...... associated with high

More information

Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 st January 31 st March 2015

Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 st January 31 st March 2015 Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 st January 31 st March 2015 1. The cumulative cases report since December 2010 and cases report during January to March 2015 During

More information

MDR AGENTS: RISK FACTORS AND THERAPEUTIC STRATEGIES

MDR AGENTS: RISK FACTORS AND THERAPEUTIC STRATEGIES MDR AGENTS: RISK FACTORS AND THERAPEUTIC STRATEGIES 1 Marin H. Kollef, MD Professor of Medicine Virginia E. and Sam J. Golman Chair in Respiratory Intensive Care Medicine Washington University School of

More information

Epidemiological and Microbiological Analysis of Ventilator-Associated Pneumonia Patients in a Public Teaching Hospital

Epidemiological and Microbiological Analysis of Ventilator-Associated Pneumonia Patients in a Public Teaching Hospital 482 BJID 2007; 11 (October) Epidemiological and Microbiological Analysis of Ventilator-Associated Pneumonia Patients in a Public Teaching Hospital João Manoel da Silva Júnior 1, Ederlon Rezende 1, Thaís

More information

Inadequate Empiric Antibiotic Therapy among Canadian. Hospitalized Solid-Organ Transplant Patients: Incidence and Impact on Hospital Mortality

Inadequate Empiric Antibiotic Therapy among Canadian. Hospitalized Solid-Organ Transplant Patients: Incidence and Impact on Hospital Mortality Inadequate Empiric Antibiotic Therapy among Canadian Hospitalized Solid-Organ Transplant Patients: Incidence and Impact on Hospital Mortality by Bassem Hamandi A thesis submitted in conformity with the

More information

Ventilator Associated Pneumonia. ICU Fellowship Training Radboudumc

Ventilator Associated Pneumonia. ICU Fellowship Training Radboudumc Ventilator Associated Pneumonia ICU Fellowship Training Radboudumc Attributable mortality VAP Meta-analysis of individual patient data from randomized prevention studies Attributable mortality mainly results

More information

ISF criteria (International sepsis forum consensus conference of infection in the ICU) Secondary peritonitis

ISF criteria (International sepsis forum consensus conference of infection in the ICU) Secondary peritonitis Appendix with supplementary material. This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Supplementary Tables Table S1. Definitions

More information

Objective: To assess the incidence of healthcare-associated infections (HAI) and the prevalence

Objective: To assess the incidence of healthcare-associated infections (HAI) and the prevalence Abstract Objective: To assess the incidence of healthcare-associated infections (HAI) and the prevalence of pathogens across all pediatric units within a single hospital, and trends in pediatric HAI over

More information

SURVEILLANCE BLOODSTREAM INFECTIONS IN BELGIAN HOPITALS ( SEP ) RESULTS ANNUAL REPORT data

SURVEILLANCE BLOODSTREAM INFECTIONS IN BELGIAN HOPITALS ( SEP ) RESULTS ANNUAL REPORT data SURVEILLANCE BLOODSTREAM INFECTIONS IN BELGIAN HOPITALS ( SEP ) RESULTS ANNUAL REPORT data 2000-2014 SEP Workgroup Meeting 24 June 2015 Dr. Naïma Hammami Dr. Marie-Laurence Lambert naima.hammami@wiv-isp.be

More information

NOSOCOMIAL pneumonia (NP) is the second. Nosocomial Pneumonia in a Pediatric Intensive Care Unit

NOSOCOMIAL pneumonia (NP) is the second. Nosocomial Pneumonia in a Pediatric Intensive Care Unit Nosocomial Pneumonia in a Pediatric Intensive Care Unit P.K. Patra, M. Jayashree, S. Singhi, P. Ray* and A.K. Saxena** From the Departments of Pediatrics, Microbiology* and Radiodiagnosis** Postgraduate

More information

Antibiotics for ventilator-associated pneumonia(review)

Antibiotics for ventilator-associated pneumonia(review) Cochrane Database of Systematic Reviews Antibiotics for ventilator-associated pneumonia(review) ArthurLE,KizorRS,SelimAG,vanDrielML,SeoaneL ArthurLE,KizorRS,SelimAG,vanDrielML,SeoaneL. Antibiotics for

More information

Ventilator-associated pneumonia after pediatric cardiac surgery in southern Taiwan

Ventilator-associated pneumonia after pediatric cardiac surgery in southern Taiwan J Microbiol Immunol Infect. 2009;42:413-419 Ventilator-associated pneumonia after pediatric cardiac surgery in southern Taiwan Chia-Wan Tang 1, Po-Yen Liu 1, Yung-Feng Huang 1, Jun-Yen Pan 2, Susan Shin-Jung

More information

Clinical Characteristics of Nursing and Healthcare-Associated Pneumonia: A Japanese Variant of Healthcare-Associated Pneumonia

Clinical Characteristics of Nursing and Healthcare-Associated Pneumonia: A Japanese Variant of Healthcare-Associated Pneumonia ORIGINAL ARTICLE Clinical Characteristics of Nursing and Healthcare-Associated Pneumonia: A Japanese Variant of Healthcare-Associated Pneumonia Tadashi Ishida, Hiromasa Tachibana, Akihiro Ito, Hiroshige

More information

VAP Are strict diagnostic criteria advisable?

VAP Are strict diagnostic criteria advisable? VAP Are strict diagnostic criteria advisable? Javier Garau, MD, PhD 18th Infection and Sepsis Symposium, Porto, 27th February 2013 Limitations of current definitions Alternatives -Streamlined definition

More information

Implementation and evaluation of the impact of a "ventilator-bundle at Kinshasa University Clinics: Before and after study.

Implementation and evaluation of the impact of a ventilator-bundle at Kinshasa University Clinics: Before and after study. Research Article http://www.alliedacademies.org/journal-infectious-diseases-medical-microbiology/ Implementation and evaluation of the impact of a "ventilator-bundle at Kinshasa University Clinics: Before

More information

(multidrug-resistant Pseudomonas aeruginosa; MDRP)

(multidrug-resistant Pseudomonas aeruginosa; MDRP) 220 2009 (multidrug-resistant Pseudomonas aeruginosa; MDRP) 21 4 1 21 10 4 amikacin (AMK), imipenem/cilastatin (IPM), ciprofloxacin (CPFX) multidrug-resistant Pseudomonas aeruginosa (MDRP) CHROMagar TM

More information

Antisepsis Bath and Oral.. Should We Change Practice? DR AZMIN HUDA ABDUL RAHIM

Antisepsis Bath and Oral.. Should We Change Practice? DR AZMIN HUDA ABDUL RAHIM Antisepsis Bath and Oral.. Should We Change Practice? DR AZMIN HUDA ABDUL RAHIM Chlorhexidine Exposure in ICU Chlorhexidine gluconate Long acting topical antiseptic In use since 1954 Water soluble Remains

More information

Postoperative pneumonia following cardiac surgery in non-ventilated patients versus mechanically ventilated patients: is there any difference?

Postoperative pneumonia following cardiac surgery in non-ventilated patients versus mechanically ventilated patients: is there any difference? Allou et al. Critical Care (2015) 19:116 DOI 10.1186/s13054-015-0845-5 RESEARCH Postoperative pneumonia following cardiac surgery in non-ventilated patients versus mechanically ventilated patients: is

More information

Care Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT

Care Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT Care Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT Target Audience: All MHS employed providers within Primary Care, Urgent Care, and In-Hospital Care. The secondary audience

More information

Outbreak investigation of nosocomial infections

Outbreak investigation of nosocomial infections Definitions Outbreak investigation of nosocomial infections School of Public Health, HSUM March 2012 Walter Popp, University Clinics Essen, Germany Epidemia increased number of cases, limited in time and

More information

Protocols for Laboratory Verification of Performance of the BioFire FilmArray Pneumonia Panel

Protocols for Laboratory Verification of Performance of the BioFire FilmArray Pneumonia Panel Protocols for Laboratory Verification of Performance of the BioFire FilmArray Pneumonia Panel Laboratory Protocols for Use with a ZeptoMetrix NATtrol Verification Panel Purpose The Clinical Laboratory

More information

Prognostic factors of nosocomial pneumonia in general wards: a prospective multivariate analysis in Japan

Prognostic factors of nosocomial pneumonia in general wards: a prospective multivariate analysis in Japan Vol. 96 (2002) 18^23 Prognostic factors of nosocomial pneumonia in general wards: a prospective multivariate analysis in Japan Y.TAKANO, O. SAKAMOTO, M. SUGA, H. MURANAKA AND M. ANDO First Department of

More information

PERCUTANEOUS DILATATIONAL TRACHEOSTOMY

PERCUTANEOUS DILATATIONAL TRACHEOSTOMY PERCUTANEOUS DILATATIONAL TRACHEOSTOMY GM KOKSAL *, NC SAYILGAN * AND H OZ ** Abstract Background: The aim of this study was to investigate the rate, timing, the incidence of complications of percutaneous

More information

Computer-Assisted Surveillance for Detecting Clonal Outbreaks of Nosocomial Infection

Computer-Assisted Surveillance for Detecting Clonal Outbreaks of Nosocomial Infection JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2004, p. 1170 1175 Vol. 42, No. 3 0095-1137/04/$08.00 0 DOI: 10.1128/JCM.42.3.1170 1175.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.

More information

Sepsi: nuove definizioni, approccio diagnostico e terapia

Sepsi: nuove definizioni, approccio diagnostico e terapia GIORNATA MONDIALE DELLA SEPSI DIAGNOSI E GESTIONE CLINICA DELLA SEPSI Giovedì, 13 settembre 2018 Sepsi: nuove definizioni, approccio diagnostico e terapia Nicola Petrosillo Società Italiana Terapia Antiinfettiva

More information

Treatment of febrile neutropenia in patients with neoplasia

Treatment of febrile neutropenia in patients with neoplasia Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece

More information

Enterobacter aerogenes

Enterobacter aerogenes Enterobacter aerogenes Piagnerelli M 1, Carlier E 1, Deplano A 3, Lejeune P 1, Govaerts D 2 1 Departments of Intensive Care and 2 Microbiology, A. Vésale Hospital. 6110 Montigny-le-Tilleul. 3 Department

More information

Cross-colonisation with Pseudomonas aeruginosa of patients in an intensive care unit

Cross-colonisation with Pseudomonas aeruginosa of patients in an intensive care unit Thorax 1998;53:1053 1058 1053 Internal Medicine, University Hospital Maastricht, Maastricht, The DCJJBergmans S van der Geest R M Wilting P W de Leeuw Internal Medicine, University Hospital Utrecht, Utrecht,

More information

A Two-Year Analysis of Risk Factors and Outcome in Patients with Bloodstream Infection

A Two-Year Analysis of Risk Factors and Outcome in Patients with Bloodstream Infection Jpn. J. Infect. Dis., 56, 1-7, 2003 Original Article A Two-Year Analysis of Risk Factors and Outcome in Patients with Bloodstream Infection Andrea Endimiani, Antonio Tamborini, Francesco Luzzaro, Gianluigi

More information

Application of a Nano-antimicrobial film to prevent ventilatorassociated pneumonia: A pilot study

Application of a Nano-antimicrobial film to prevent ventilatorassociated pneumonia: A pilot study Title Application of a Nano-antimicrobial film to prevent ventilatorassociated pneumonia: A pilot study Author(s) Li, W; Ma, X; Peng, Y; Cao, J; Loo, WTY; Hao, L; Cheung, MNB; Chow, LWC; Jin, LJ Citation

More information